Get the Stockscreener App
160.79
0.19%
-0.31
After Hours:
161.10
0.31
+0.19%
Novartis Ag Adr stock is traded at $160.79, with a volume of 3.15M.
It is down -0.19% in the last 24 hours and up +12.78% over the past month.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
See More
Previous Close:
$161.10
Open:
$162.53
24h Volume:
3.15M
Relative Volume:
1.28
Market Cap:
$303.67B
Revenue:
$54.66B
Net Income/Loss:
$13.58B
P/E Ratio:
22.91
EPS:
7.0171
Net Cash Flow:
$16.05B
1W Performance:
+6.40%
1M Performance:
+12.78%
6M Performance:
+8.75%
1Y Performance:
+31.14%
1-Day Range:
$160.40
$164.06
1-Week Range:
$152.02
$164.06
52-Week Range:
$121.98
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Name
Novartis Ag Adr
Sector
Industry
Phone
-
Address
-
Compare NVS vs LLY, JNJ, ABBV, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
160.79 | 303.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,417.54 | 1.26T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
273.20 | 657.68B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
294.89 | 521.11B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
149.52 | 368.89B | 65.51B | 8.93B | 14.12B | 3.5532 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-26 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-09-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-09-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-11-26 | Upgrade | Argus | Hold → Buy |
| Jan-27-26 | Initiated | Citigroup | Buy |
| Jan-06-26 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-12-25 | Downgrade | Goldman | Neutral → Sell |
| Aug-08-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-13-25 | Downgrade | UBS | Buy → Neutral |
| Feb-12-25 | Initiated | Morgan Stanley | Underweight |
| Feb-04-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Dec-04-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Sep-11-24 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-05-24 | Downgrade | Goldman | Buy → Neutral |
| Sep-03-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-24 | Downgrade | Deutsche Bank | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-23-24 | Initiated | BMO Capital Markets | Market Perform |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-25-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-26-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-27-23 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-26-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-05-22 | Upgrade | Stifel | Hold → Buy |
| Sep-15-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| May-09-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-10-22 | Resumed | Citigroup | Buy |
| Dec-14-21 | Downgrade | Redburn | Buy → Neutral |
| Dec-06-21 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-03-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Sep-20-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-22-21 | Initiated | Bernstein | Mkt Perform |
| Mar-10-21 | Downgrade | Argus | Buy → Hold |
| Feb-01-21 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Sep-10-20 | Upgrade | UBS | Neutral → Buy |
| Sep-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-15-20 | Upgrade | Citigroup | Neutral → Buy |
| Mar-10-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-25-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-10-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-02-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Underperform → Buy |
| May-29-18 | Downgrade | HSBC Securities | Buy → Hold |
| May-25-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jan-25-18 | Reiterated | Leerink Partners | Outperform |
| Dec-06-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jul-26-17 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jul-05-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Mar-09-17 | Initiated | Liberum | Buy |
View All
Novartis Ag Adr Stock (NVS) Latest News
Novartis AG (NVS) Seasonal returns chart - Yahoo Finance UK
Novartis AG (NVS) Stock Up 3.2% but GF Value Says Overvalued -- GF Score: 79/100 - GuruFocus
China Upends Global Drug Development With Cheap and Rapid Human Trials - Bloomberg.com
INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised - Zacks Investment Research
Should You Buy Royalty Pharma Stock Before Nov. 4? - The Motley Fool
Novartis AG (NVS) Stock Forecasts - Yahoo! Finance Canada
Novartis AG : Bernstein reiterates its Neutral rating - www.marketscreener.com
Novartis AG : JP Morgan reiterates its Buy rating - marketscreener.com
Novartis AG Stock 12‑Month Price Target Raised to $158.2, Implies 1% Upside - TradingView
Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight - GlobeNewswire Inc.
How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3? - Zacks Investment Research
The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie - Zacks Investment Research
Novartis AG (NVS) Stock Forecasts - Yahoo Finance
What Novartis (NVS) Said on Its Q3 Earnings Call - Yahoo Finance
Novartis AG (NVS) (Q3 2026) Earnings Call Highlights: Raised Gui - GuruFocus
Novartis AG (NVS) (Q3 2026) Earnings Call Highlights: Raised Guidance and Priority Brand ... - Yahoo Finance
Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9B Avidity HitNovartis (NYSE:NVS) - Benzinga
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential - Zacks Investment Research
NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss - Zacks Investment Research
Novartis takes $1.9bn writedown on key drug after blockbuster Avidity acquisition - Financial Times
NOVARTIS AG N (NOTA.DU) Q3 FY2026 earnings call transcript - Yahoo Finance
The Zacks Analyst Blog Highlights Intel, Novartis AG, Itau Unibanco and AMREP - Yahoo Finance
Novartis Raises Outlook on Growth of New Medicines - Bloomberg.com
Novartis lifts profit outlook as new medicines counter generic erosion (NVS:NYSE) - Seeking Alpha
Novartis reports Q3 core EPS $2.46 vs. $2.25 last year - TipRanks
Novartis AG reports results for the quarter ended September 30Earnings Summary - TradingView
Novartis Q3 Core Earnings, Net Sales Increase; 2026 Net Sales Growth Outlook Maintained - Yahoo Finance
Novartis: Q3 Earnings Snapshot - Yahoo Finance
Top Analyst Reports for Intel, Novartis & Itau Unibanco - Zacks Investment Research
Earnings To Watch: Novartis AG (XSWX:NOVN) Q3 2026 -- GF Value Sees 8% Downside - Yahoo Finance
Novartis AG : UBS sticks Neutral - marketscreener.com
Novartis MS Pill Trials Trigger Analyst Skepticism on Peak Sales - Bloomberg.com
Novartis AG : Gets a Neutral rating from RBC - marketscreener.com
Novartis AG : Gets a Neutral rating from Barclays - marketscreener.com
Novartis: Strong Drug Growth Faces A Tougher Test As Patent Losses And Pipeline Setbacks Mount - Seeking Alpha
Novartis Reports Positive Results from Late-stage Studies for Remibrutinib - marketscreener.com
Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity - Yahoo Finance
Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple SclerosisSlideshow - Seeking Alpha
Novartis AG Remibrutinib in MS Investor Call Transcript - GuruFocus
Novartis AG (NVS) Stock Down 3.3% but Still Overvalued -- GF Score: 75/100 - GuruFocus
Novartis AG : RBC is Neutral - marketscreener.com
Novartis Multiple Sclerosis Pill Missed Expectations in Key Study - Bloomberg.com
Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib - Reuters
Novartis’ Kisqali Cuts Death Risk 19% in Breast Cancer Study - Bloomberg.com
Novartis AG Stock (NVS) Moved Down by 3.61% on Oct 23: Facts Behind the Movement - TradingKey
Novartis AG Estimates – BX:NOT - TradingView
Novartis AG expected to post earnings of $2.29 a shareEarnings Preview - TradingView
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy - Zacks Investment Research
Novartis AG Lobbying Profile, 2004 - OpenSecrets
Earnings Preview: Novartis AG to Report Financial Results on October 27 - Moomoo
Novartis Ag Adr Stock (NVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novartis Ag Adr Stock (NVS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bulto Carulla Victor | Officer |
Apr 30 '26 |
Proposed Sale |
148.10 |
6,800 |
1,007,093 |
0 |
| Marshall Fiona | Officer |
Feb 12 '26 |
Proposed Sale |
161.35 |
30,743 |
4,960,277 |
0 |
| Bulto Carulla Victor | Officer |
Feb 09 '26 |
Proposed Sale |
156.21 |
7,500 |
1,171,576 |
0 |
7.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):